Ola Kleveland

1.1k total citations · 1 hit paper
15 papers, 498 citations indexed

About

Ola Kleveland is a scholar working on Cardiology and Cardiovascular Medicine, Immunology and Surgery. According to data from OpenAlex, Ola Kleveland has authored 15 papers receiving a total of 498 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cardiology and Cardiovascular Medicine, 7 papers in Immunology and 5 papers in Surgery. Recurrent topics in Ola Kleveland's work include Acute Myocardial Infarction Research (7 papers), Atherosclerosis and Cardiovascular Diseases (7 papers) and Cardiac Fibrosis and Remodeling (6 papers). Ola Kleveland is often cited by papers focused on Acute Myocardial Infarction Research (7 papers), Atherosclerosis and Cardiovascular Diseases (7 papers) and Cardiac Fibrosis and Remodeling (6 papers). Ola Kleveland collaborates with scholars based in Norway, United States and United Kingdom. Ola Kleveland's co-authors include Thor Ueland, Lars Gullestad, Pål Aukrust, Jan Kristian Damås, Rune Wiseth, Bjørn Bendz, Kaspar Broch, Brage H. Amundsen, Svend Aakhus and Gabor Kunszt and has published in prestigious journals such as Circulation, International Journal of Molecular Sciences and European Heart Journal.

In The Last Decade

Ola Kleveland

14 papers receiving 497 citations

Hit Papers

Effect of a single dose of the interleukin-6 receptor ant... 2016 2026 2019 2022 2016 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial
    2016 288 citations Ola Kleveland, Gabor Kunszt et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ola Kleveland Norway 9 229 201 200 131 106 15 498
Gabor Kunszt Norway 5 160 0.7× 146 0.7× 227 1.1× 100 0.8× 81 0.8× 5 449
Michael Gambill United States 4 151 0.7× 278 1.4× 246 1.2× 97 0.7× 123 1.2× 5 493
Ryan Melchior United States 7 232 1.0× 378 1.9× 351 1.8× 124 0.9× 163 1.5× 9 708
Claudia Oddi United States 5 182 0.8× 347 1.7× 422 2.1× 111 0.8× 157 1.5× 6 713
Mohammadreza Akhavanpoor Germany 17 332 1.4× 136 0.7× 131 0.7× 96 0.7× 207 2.0× 27 662
George Mueller United States 3 145 0.6× 260 1.3× 233 1.2× 92 0.7× 117 1.1× 5 453
He-Ping Guo China 11 196 0.9× 116 0.6× 269 1.3× 72 0.5× 47 0.4× 20 474
Roshanak Robati United States 5 137 0.6× 315 1.6× 296 1.5× 86 0.7× 142 1.3× 6 535
Hirotaka Kimura Japan 10 159 0.7× 171 0.9× 141 0.7× 142 1.1× 145 1.4× 19 558
Jeffrey R. Crawford United States 10 77 0.3× 150 0.7× 164 0.8× 52 0.4× 83 0.8× 11 439

Countries citing papers authored by Ola Kleveland

Since Specialization
Citations

This map shows the geographic impact of Ola Kleveland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ola Kleveland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ola Kleveland more than expected).

Fields of papers citing papers by Ola Kleveland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ola Kleveland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ola Kleveland. The network helps show where Ola Kleveland may publish in the future.

Co-authorship network of co-authors of Ola Kleveland

This figure shows the co-authorship network connecting the top 25 collaborators of Ola Kleveland. A scholar is included among the top collaborators of Ola Kleveland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ola Kleveland. Ola Kleveland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Dahl, Tuva B., Kaspar Broch, Anne Kristine Anstensrud, et al.. (2025). The N-6 methyladenosine dynamics in STEMI and the effect of IL-6 inhibition - a hypothesis generating sub-study of the ASSAIL-MI trial. Frontiers in Immunology. 16. 1532325–1532325.
2.
Woxholt, Sindre, Thor Ueland, Pål Aukrust, et al.. (2024). Effect of tocilizumab on endothelial and platelet-derived CXC-chemokines and their association with inflammation and myocardial injury in STEMI patients undergoing primary PCI. International Journal of Cardiology. 418. 132613–132613. 1 indexed citations
3.
Kong, Xiang Yi, Kaspar Broch, Lars Gullestad, et al.. (2024). Circular RNA Profile in Atherosclerotic Disease: Regulation during ST-Elevated Myocardial Infarction. International Journal of Molecular Sciences. 25(16). 9014–9014. 2 indexed citations
4.
Thorand, Barbara, Marc J. George, Sander W. van der Laan, et al.. (2023). Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis. Circulation. 149(9). 669–683. 22 indexed citations
5.
Woxholt, Sindre, Thor Ueland, Pål Aukrust, et al.. (2023). Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab. Open Heart. 10(2). e002301–e002301. 6 indexed citations
6.
Helseth, Ragnhild, Ola Kleveland, Thor Ueland, et al.. (2021). Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction. Open Heart. 8(1). e001492–e001492. 7 indexed citations
7.
George, Marc J., Ola Kleveland, Jorge García‐Hernández, et al.. (2020). Novel Insights Into the Effects of Interleukin 6 Antagonism in Non–ST‐Segment–Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform. Journal of the American Heart Association. 9(12). e015628–e015628. 17 indexed citations
8.
Anstensrud, Anne Kristine, Sindre Woxholt, Kapil Sharma, et al.. (2019). Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI). Open Heart. 6(2). e001108–e001108. 35 indexed citations
9.
Kleveland, Ola, Thor Ueland, Gabor Kunszt, et al.. (2018). Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction. International Journal of Cardiology. 271. 1–7. 27 indexed citations
10.
Nilsson, Per H., Søren Erik Pischke, Ola Kleveland, et al.. (2018). IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction. Frontiers in Immunology. 9. 2035–2035. 20 indexed citations
11.
Ueland, Thor, Ola Kleveland, Annika E. Michelsen, et al.. (2018). Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction. International Journal of Cardiology. 274. 348–350. 10 indexed citations
12.
Ueland, Thor, Ola Kleveland, Annika E. Michelsen, et al.. (2018). Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction. Open Heart. 5(2). e000765–e000765. 15 indexed citations
13.
Holte, Espen, Ola Kleveland, Thor Ueland, et al.. (2017). Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction. Heart. 103(19). 1521–1527. 40 indexed citations
14.
Kleveland, Ola, Gabor Kunszt, Thor Ueland, et al.. (2016). Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. European Heart Journal. 37(30). 2406–2413. 288 indexed citations breakdown →
15.
Kleveland, Ola, et al.. (2001). Hypergastrinemia as a Cause of Chromogranin A Increase in Blood in Patients Suspected to Have Neuroendocrine Tumor. Digestion. 64(2). 71–74. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gabor Kunszt Breakdown of academic impact, for papers by Michael Gambill Breakdown of academic impact, for papers by Ryan Melchior Breakdown of academic impact, for papers by Claudia Oddi Breakdown of academic impact, for papers by Mohammadreza Akhavanpoor Breakdown of academic impact, for papers by George Mueller Breakdown of academic impact, for papers by He-Ping Guo Breakdown of academic impact, for papers by Roshanak Robati Breakdown of academic impact, for papers by Hirotaka Kimura Breakdown of academic impact, for papers by Jeffrey R. Crawford
Rankless by CCL
2026